Tim Gallagher shared an article with you from Pocket

Tim Gallagher shared with you:       Wild clinical success stats here           Forget the tech bubble. It's the biotech bubble you should worry about – Quartz       qz.com

Don't have time to view this now? Sign up for Pocket and view this page later.         Get Pocket

You are receiving this email because a friend shared to your email address from Pocket. For support requests, please contact us by going to our support page. Notification Settings Privacy Policy Read It Later, Inc., 731 Market Street Suite 410, San Francisco, CA 94108, USA © 2013 Read It Later, Inc. All Rights Reserved.

Tim Gallagher shared an article with you from Pocket

Tim Gallagher shared with you:       Eye-opening           The Case Against Early Cancer Detection       fivethirtyeight.com

Don't have time to view this now? Sign up for Pocket and view this page later.         Get Pocket

You are receiving this email because a friend shared to your email address from Pocket. For support requests, please contact us by going to our support page. Notification Settings Privacy Policy Read It Later, Inc., 731 Market Street Suite 410, San Francisco, CA 94108, USA © 2013 Read It Later, Inc. All Rights Reserved.

Tim Gallagher shared an article with you from Pocket

Tim Gallagher shared with you:       Very exciting and very close to fruition. (Except Theranos.)           10 Ideas That Are About To Change Medicine Forever       businessinsider.com

Don't have time to view this now? Sign up for Pocket and view this page later.         Get Pocket

You are receiving this email because a friend shared to your email address from Pocket. For support requests, please contact us by going to our support page. Notification Settings Privacy Policy Read It Later, Inc., 731 Market Street Suite 410, San Francisco, CA 94108, USA © 2013 Read It Later, Inc. All Rights Reserved.

Tim Gallagher shared an article from Pocket: Pharmaceutical Scouts Seek New Star Drugs for Cancer, Diabetes

Tim Gallagher shared with you:       Here's a view inside drug partnering, with the main point being that Big Pharma is much more open to collaboration. That isn't news to most, but still good personal insights in the article. I'm surprised, though at one of the stats in the article: 33% of all Big Pharma leads are in-licensed. Put another way, 2/3rds of all Big Pharma programs are still internally sourced. That doesn't seem right - internal discovery in Big Pharma seems to me to have shrunken to a minority activity - maybe 25% of all big Pharma R&D. What's your impression?           Pharmaceutical Scouts Seek New Star Drugs for Cancer, Diabetes       online.wsj.com

Don't have time to view this now? Sign up for Pocket and view this page later.         Get Pocket

You are receiving this email because a friend shared to your email address from Pocket. For support requests, please contact us by going to our support page. Notification Settings Privacy Policy Read It Later, Inc., 731 Market Street Suite 410, San Francisco, CA 94108, USA © 2013 Read It Later, Inc. All Rights Reserved.

Molecular Diagnostics Are in a Rut. The Industry Needs the FDA

Tim Gallagher shared with you:       A good look at the muddled state of molecular diagnostics.           Molecular Diagnostics Are in a Rut. The Industry Needs the FDA       xconomy.com

Don't have time to view this now? Sign up for Pocket and view this page later.         Get Pocket

You are receiving this email because a friend shared to your email address from Pocket. For support requests, please contact us by going to our support page. Notification Settings Privacy Policy Read It Later, Inc., 731 Market Street Suite 410, San Francisco, CA 94108, USA © 2013 Read It Later, Inc. All Rights Reserved.